检索结果 - Albert Assad

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase

    A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the... 由 Sarah K. Tasian, Albert Assad, Deborah Hunter, Yining Du, Mignon L. Loh

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Fully convolutional neural networks improve abdominal organ segmentation

    Fully convolutional neural networks improve abdominal organ segmentation 由 Bennett A. Landman, Meg F. Bobo, Yuankai Huo, Yuang Yao, Shunxing Bao, John Virostko, Andrew J. Plassard, Ilwoo Lyu, Albert Assad, Richard G. Abramson, Melissa A. Hilmes

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma

    Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma 由 Stephen M. Ansell, Steven M. Horwitz, Andreas Engert, Khuda Dad Khan, Thomas S. Lin, Roger Strair, Tibor Keler, Robert F. Graziano, Diann Blanset, Michael Yellin, Steven Fischkoff, Albert Assad, Peter Borchmann

    出版 2007
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

    Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results 由 Srđan Verstovšek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Hui‐Ling Zhen, Muriel Granier, Albert Assad, Mario Cazzola, Hagop M. Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi

    出版 2017
    获取全文 获取全文
    Carta
    加到收藏夹
    Saved in:
  5. 5
    Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer

    Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer 由 David R. Fogelman, Antonio Cubillo, Pilar García‐Alfonso, María Luisa Limón Mirón, John Nemunaitis, Daniel Flora, Christophe Borg, Laurent Mineur, J.M. Viéitez, Allen Lee Cohn, Gene Saylors, Albert Assad, Julie Switzky, Li Zhou, Johanna C. Bendell

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis

    Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis 由 John Mascarenhas, Moshe Talpaz, Vikas Gupta, Lynda Foltz, Michael R. Savona, Ronald Paquette, A. Robert Turner, Paul Coughlin, Elliott F. Winton, Timothy C. Burn, Peter O’Neill, Jason A. Clark, Deborah Hunter, Albert Assad, Ronald Hoffman, Srđan Verstovšek

    出版 2016
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results

    Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results 由 Abdulraheem Yacoub, Uma Borate, Raajit K. Rampal, Haris Ali, Eunice S. Wang, Aaron T. Gerds, Gabriela S. Hobbs, Marina Kremyanskaya, Elliott F. Winton, Casey L. O’Connell, Swati Goel, Stephen T. Oh, Gary J. Schiller, James McCloskey, Jeanne Palmer, Houston Holmes, Steven Hager, Albert Assad, Susan Erickson‐Viitanen, Feng Zhou, Naval Daver

    出版 2024
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: